- Biopharmaceutical company Organicell Regenerative Medicine Inc OCEL plans to expand into the skincare and haircare industries in partnership with Beauty Health Co SKIN.
- BeautyHealth's Hydrafacial, with Organicell, will create the first to-market exosome booster for their patented Hydrafacial device.
- Hydrafacial's new exosome booster will be available early next year.
- Organicell is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics and regenerative medicine.
- Organicell's science team will work with Hydrafacial to prove the efficacy of how this new booster application may reduce inflammation, increase collagen, and increase elastin.
- "This partnership is the first of many we are working on in the aesthetic and hair space," said Organicell's CEO, Matt Sinnreich.
- Last week, Organicell secured an additional $11 million in financing in preparation for clinical trial enrollment.
- Organicell has been approved by the FDA to conduct Phase I/II clinical trials on their investigational new drug, Zofin.
- Price Action: OCEL shares are trading higher by 4.13% at $0.05 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in